DNDI-6148 is a novel preclinical candidate for the treatment of visceral leishmaniasis.

2243909-59-1

C16H14BN5O3

335.13

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years